This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Alnylam Reports Positive Data on Lumasiran in Renal Disease
by Zacks Equity Research
Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.
The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street
3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry
by Indrajit Bandyopadhyay
Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well.
5 Biotech Stocks to Boost Your Portfolio's Health This Year
by Kinjel Shah
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio.
The Zacks Analyst Blog Highlights: UnitedHealth, United Technologies, Eni, Sanofi and Discovery
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, United Technologies, Eni, Sanofi and Discovery
Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
by Zacks Equity Research
Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.
Top Research Reports for UnitedHealth, United Technologies & Eni
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), United Technologies (UTX) and Eni (E).
Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data
by Zacks Equity Research
Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
by Zacks Equity Research
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
BioMarin Begins Mid Stage Study on Gene Therapy Candidate
by Zacks Equity Research
BioMarin (BMRN) initiates a mid-stage study to evaluate its gene therapy candidate, valoctocogene roxaparvovec for treating in AAV5+ severe hemophilia A.
Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.
Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View
by Zacks Equity Research
Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.
Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View
by Zacks Equity Research
Regeneron's (REGN) first-quarter results were mixed as earnings beat expectations while sales missed the same. Nevertheless, Eylea sales were impressive.
What's in the Offing for Regeneron (REGN) in Q1 Earnings?
by Zacks Equity Research
Investors are expected to focus on Eylea's performance and Dupixent's uptake when Regeneron Pharmaceuticals, Inc. (REGN) reports first-quarter 2018 results on May 3.
Sanofi's (SNY) Earnings Beat Estimates in Q1, Sales Miss Mark
by Zacks Equity Research
Sanofi (SNY) beat earnings but missed sales estimates in the first quarter of 2018 owing to exchange rate effects and struggling diabetes and cardiovascular unit.
BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat
by Zacks Equity Research
BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.
Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y
by Zacks Equity Research
Amgen (AMGN) impresses with better-than-estimated results on both counts but tweaks its sales guidance for 2018. Shares decline in after-hours trading.
Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down
by Zacks Equity Research
Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.
Shire (SHPG) Turns Down Takeda's Third Buyout Proposition
by Zacks Equity Research
Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.
Sanofi to Divest European Generic Unit, Streamline Business
by Zacks Equity Research
Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.
Top Analyst Reports for AbbVie, Berkshire & PepsiCo
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Berkshire Hathaway (BRK.B) and PepsiCo (PEP).
Alexion (ALXN) to Acquire Wilson Therapeutics for $855M
by Zacks Equity Research
Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.
Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion
by Zacks Equity Research
The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.
Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU
by Zacks Equity Research
Sanofi's (SNY) filing for its antibody cemiplimab for skin cancer and the label expansion of its marketed drug Dupixent for asthama wins acceptance from EMA.